The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online
doi:10.1084/jem.20082242
The Journal of Experimental Medicine, Vol. 206, No. 5, 1135-1147
The Rockefeller University Press, 0022-1007 $30.00
© Briot et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 5784K)
Right arrow PDF+supp data (7473K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Briot, A.
Right arrow Articles by Hovnanian, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Briot, A.
Right arrow Articles by Hovnanian, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Kallikrein 5 induces atopic dermatitis–like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome

Anaïs Briot1,2, Céline Deraison1,2,3, Matthieu Lacroix1,2, Chrystelle Bonnart1,2, Aurélie Robin1,2, Céline Besson1,2, Pierre Dubus4, and Alain Hovnanian1,2,3

1 Institut National de la Santé et de la Recherche Médicale, U563, Toulouse F-31300, France
2 Université Toulouse III Paul-Sabatier, Toulouse F-31400, France
3 Departement de Génétique Médicale, Hôpital Purpan, Centre Hospitalier Universitaire de Toulouse, Toulouse F31000, France
4 EA2406 Université Bordeaux 2 Victor Segalen, Bordeaux F-33076, France

CORRESPONDENCE Alain Hovnanian: alain.hovnanian{at}inserm.fr

Netherton syndrome (NS) is a severe genetic skin disease with constant atopic manifestations that is caused by mutations in the serine protease inhibitor Kazal-type 5 (SPINK5) gene, which encodes the protease inhibitor lymphoepithelial Kazal-type–related inhibitor (LEKTI). Lack of LEKTI causes stratum corneum detachment secondary to epidermal proteases hyperactivity. This skin barrier defect favors allergen absorption and is generally regarded as the underlying cause for atopy in NS. We show for the first time that the pro-Th2 cytokine thymic stromal lymphopoietin (TSLP), the thymus and activation-regulated chemokine, and the macrophage-derived chemokine are overexpressed in LEKTI-deficient epidermis. This is part of an original biological cascade in which unregulated kallikrein (KLK) 5 directly activates proteinase-activated receptor 2 and induces nuclear factor {kappa}B–mediated overexpression of TSLP, intercellular adhesion molecule 1, tumor necrosis factor {alpha}, and IL8. This proinflammatory and proallergic pathway is independent of the primary epithelial failure and is activated under basal conditions in NS keratinocytes. This cell-autonomous process is already established in the epidermis of Spink5–/– embryos, and the resulting proinflammatory microenvironment leads to eosinophilic and mast cell infiltration in a skin graft model in nude mice. Collectively, these data establish that uncontrolled KLK5 activity in NS epidermis can trigger atopic dermatitis (AD)–like lesions, independently of the environment and the adaptive immune system. They illustrate the crucial role of protease signaling in skin inflammation and point to new therapeutic targets for NS as well as candidate genes for AD and atopy.


A. Briot and C. Deraison contributed equally to this paper.

Abbreviations used: AD, atopic dermatitis; GR, granular layer; HRP, horseradish peroxidase; ICAM1, intercellular adhesion molecule 1; KLK, kallikrein; LC, Langerhans cell; LEKTI, lymphoepithelial Kazal-type–related inhibitor; Mdc, macrophage-derived chemokine; NHK, normal human primary keratinocytes; NS, Netherton syndrome; PAR2, proteinase-activated receptor 2; SC, stratum corneum; SPINK5, serine protease inhibitor Kazal-type 5; Tarc, thymus and activation-regulated chemokine; TSLP, thymic stromal lymphopoietin.

© 2009 Briot et al.
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS